New warning information for ADHD drugs

Share this article:
Two attention deficit hyperactivity disorder (ADHD) drugs must include new information about heart risks and psychotic behavior, the FDA said yesterday. GlaxoSmithKline’s Dexedrine and Novartis’ Ritalin will include a warning about the possible risk of sudden death and serious heart problems, Reuters reported. At press time it was unclear whether ADHD drugs from Johnson & Johnson's (Concerta) and Eli Lilly (Strattera) were also ordered to carry the warnings. The FDA's decision comes months after two separate panels of outside experts offered conflicting opinions on whether the risks warranted black box warnings.
Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.